As the global burden of thromboembolic diseases continues to rise, with the
global urokinase market valued at USD 322 million in 2025 and projected to reach
USD 486 million by 2032 at a CAGR of 6.1%, pharmaceutical
partners worldwide are seeking a reliable Urokinase Manufacturer that delivers
high purity, consistent efficacy, and strict regulatory compliance. Urokinase, a
serine protease critical for dissolving blood clots, is widely used in treating
pulmonary embolism, deep vein thrombosis, and catheter occlusion, becoming an indispensable thrombolytic agent in emergency and clinical
care. Kangyuan, a leading biopharmaceutical Urokinase Manufacturer with decades
of expertise in urinary-derived APIs, stands out with its innovative compound
enzyme extraction technology, addressing industry pain points of low purity and
viral contamination while offering tailored solutions for North America, Europe,
Asia-Pacific, and emerging markets.
What distinguishes Kangyuan as a premier Urokinase Manufacturer is its
proprietary compound enzyme extraction and dual viral inactivation process—an
innovative breakthrough that redefines urokinase production standards. Unlike
traditional manufacturers relying on single-enzyme extraction and simple
purification, which often result in low specific activity and residual
impurities, Kangyuan combines papain and trypsin in a
controlled low-temperature environment to gently extract urokinase from
high-quality male urine, preserving its native enzymatic structure. We further
integrate QAE-Sephadex chromatographic purification and ultrafiltration, followed by dual viral inactivation (dry heat + ultraviolet)
to eliminate potential pathogens, ensuring our urokinase achieves a purity of
over 99% (HPLC) and a specific activity of no less than 150,000 IU/mg·pr, far exceeding USP, EP, and ChP pharmacopeial
requirements.
As a global Urokinase Manufacturer, Kangyuan excels in navigating complex
regional regulatory frameworks, a key advantage for partners seeking seamless
market access. In North America, our urokinase complies with FDA guidelines,
including 21 CFR Part 610 viral safety requirements and eCTD format
documentation, supported by comprehensive
DMF filings to streamline ANDA or BLA applications. In Europe, we meet EMA
standards, emphasizing detailed post-marketing risk control plans and
multi-language labeling compliance, making our product a
preferred choice for hospitals and pharmaceutical distributors across the EU. In
Asia-Pacific, the fastest-growing urokinase market, we
leverage cost-efficient production to offer competitive pricing, aligning with
regional healthcare budgets while maintaining pharmaceutical-grade quality and
NMPA compliance.
Kangyuan’s competitive edge as a Urokinase Manufacturer lies in its
scalable capacity, strict quality assurance, and customer-centric service. Our
GMP-certified facilities source raw materials from a standardized collection
network, ensuring daily collection of qualified male urine to maintain a stable
supply chain. With an annual production
capacity capable of meeting global bulk demands, we can fulfill both small-batch
R&D orders and large-scale commercial supply, supporting partners in 40+
countries. Every batch undergoes rigorous testing, including specific activity
validation, impurity screening, and viral inactivation verification,
guaranteeing safety and consistency. We also offer flexible customization
options, including different potency specifications (10000-1000000 IU) and
packaging formats, tailored to regional clinical application
needs.
As the global urokinase market grows, driven by aging populations and
increasing demand for minimally invasive thrombolytic therapies, Kangyuan remains at the forefront of innovation. Our
ongoing R&D focuses on optimizing extraction processes to further enhance
product yield and reduce production costs, while expanding our regulatory
compliance to cover emerging markets in Latin America and the Middle East. Backed by decades of expertise in urinary-derived APIs and
strict quality control, Kangyuan has become a trusted Urokinase Manufacturer for
pharmaceutical companies, hospitals, and healthcare providers worldwide.
Ready to source high-purity, regulatory-compliant urokinase? Contact
Kangyuan today to discuss your specific requirements, request samples, or learn
how our novel enzyme extraction technology can elevate your thrombolytic
products and support your success in the global market.